Apollo Medical Holdings is a physician-centric integrated population health management company providing coordinated, outcomes-based medical care and serving patients in California, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid and health maintenance organizations. The company provides care coordination services to each main constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The company's physician network consists of primary care physicians, specialist physicians and hospitalists.

Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The company's product candidates comprised of: NYX 2925, which is a small molecule N-methyl-D-aspartate receptors (NMDAr) modulator being developed for the treatment of chronic pain; NYX-783, which is a small-molecule NMDAr modulator in development for the treatment of post-traumatic stress disorder; NYX-458, which is a small-molecule NMDAr modulator in development for the treatment of Parkinson's disease cognitive impairment; and AGN-241751, which is for the treatment of depressive disorder.

Axsome Therapeutics is a clinical-stage biopharmaceutical company developing therapies for the management of central nervous system (CNS) disorders. The company's CNS product candidates includes: AXS-05, which is for the treatment resistant depression and in agitation associated with Alzheimer's disease; AXS-07, which is initially being developed for the acute treatment of migraine; AXS-09, which is being developed for CNS disorders; AXS-12, which is in development for the treatment of narcolepsy; AXS-02, which is being developed for the treatment of knee osteoarthritis and chronic low back pain; and AXS-06, which is being developed for the treatment of osteoarthritis and rheumatoid arthritis.

Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. The company's KRAS inhibitor program is focused on developing inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. The company also has additional preclinical programs which include product candidates designed to address mutations and tumors where few treatment options exist. The company's clinical and preclinical programs consist of two product candidates: sitravatinib, a multi-kinase inhibitor and MRTX849, a KRAS G12C inhibitor. The company has several discovery programs, including a preclinical program for a KRAS G12D inhibitor.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

Simply Good Foods is a developer, marketer and seller of nutritional foods and snacking products. The company's product portfolio consists primarily of nutrition bars, ready-to-drink shakes, snacks and confectionery products marketed under the Atkins?, SimplyProtein?, and Atkins Endulge? brand names. The Atkins brand approach focuses on a healthy eating approach with reduced levels of refined carbohydrates and sugars and encourages the consumption of lean protein, fiber, fruits, vegetables and healthy fats. Through third-party partnerships, the company provides complementary Atkins branded frozen meals.

Taylor Devices is engaged in the design, development, manufacture and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment and structures. These products include: Seismic Dampers, which mitigate the effects of earthquake tremors on structures; Fluidicshoks?, which are shock absorbers for use in the defense, aerospace and commercial industry; Crane and Industrial Buffers, which used for industrial application on cranes, ships, container ships, railroad cars, truck docks, ladle and ingot cars, ore trolleys and car stops; and Self-Adjusting Shock Absorbers, which are designed for high cycle application in heavy industry.